Table 3. Data used in to calibrate the model.

Module	Observable	Value
1	Prevalence of calcified NCC lesions (with or without other lesions) within the adult population	20% for similar endemic communities in Peru–see [17] and S2 Data
1	Share of individuals with NCC that have a single lesion	72.5% (95% CI: 66.6–78.4%) global average, see [17, 22, 28–32] † and Fig A in S1 Text
1	Share of individuals with NCC that have two lesions	16.9% (95% CI: 11.7–22.0%) global average, see [17, 22, 29, 30] † and Table A in S1 Text
2	Added lifetime epilepsy prevalence associated with neurocysticercosis	2.10% [1.05–3.69%], estimated using Latin America figures, see [2, 67] † & S1 Text
2	Share of never-treated calcified parenchymal NCC cases with NCC-driven epilepsy that have “long-term” active epilepsy	66.2% [53.7–77.2%] for North-West Peru–see S2 Text and dataset in S1 Data
2	Share of never treated NCC cases with active epilepsy and solely parenchymal lesions that have at least one non-calcified lesion	15.9% [10.3–23.1%] for North-West Peru–see S2 Text and dataset in S1 Data
3	Share of all NCC cases that have extra-parenchymal lesions in Peru (at community level)	Likely between 0.3% and 5% based on field data from Peru (see S2 Text for details). To be improved through field studies. 3% selected for this specific calibration.
3	Share of all clinical cases with ICH or hydrocephalus that have parenchymal lesions only	8.6% [0.0–17.3%] [54, 68–71]†, global average

^† Value not directly taken from the reference but obtained through process explained in S1 Text, Fig A Table A in S1 Text, S2 Text, S1 and S2 Data.